Development of new approaches for immunotherapy of non-small cell lung cancer

Recruiting

• Conditions: C34; Malignant neoplasm of bronchus and lung

• Registration Number: DRKS00029641
• Lead Sponsor: Molekulare PneumologieUniversitätsklinikum Erlangen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Lung tumor patients and control patients with indication for VATS:
Male and female patients 18 years of age and older with a diagnosis of lung cancer who meet the following additional criteria during clinical intervention will be included:
-Completion of a thoracoscopic-guided (VATS = video-assisted thoracic surgery) or open surgical procedure on the lung; and
-performance of a blood sampling procedure and/or
-performing an ultrasound-guided, percutaneous diagnostic or therapeutic puncture of the pleural cavity (effusion, empyema) or a pleural mass and/or
-performance of a bronchoscopy using a flexible or rigid technique (with endobronchial ultrasound: EBUS, if necessary) and/or
-Performing a bronchoscopy with bronchial lavage.

Healthy controls:
-Healthy adults with no past or current tumor diagnosis.
-Non-smokers
Smoker controls:
-Healthy adults with no past or current tumor diagnosis.
-Regular tobacco consumption for at least 1 year.

Exclusion Criteria

Lung tumor patients and control patients with indications for VATS:
-Autoimmune diseases
-Severe chron. Diseases
-Other cancer types

Healthy controls and smokers:
-Autoimmune diseases
-Severe chron. Diseases
-Malignant diseases

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Collection of lung tissue, BAL and blood samples. Collection of immunological parameters by flow cytometry, cell culture, ELISA and RNA analysis. Survey of epidemiological parameters by questionnaires.